Hubungan Pemberian N-Acetylcysteine Terhadap Risiko Terjadinya Hepatotoksisitas Pada Pasien Pengguna Obat Anti Tuberkulosis di RSUD Pasar Rebo

Dini Permata Sari, Yuni Arsita Fitriyani, Fajar Arsita Amirulah

Abstract


Hepatotoksisitas adalah salah satu efek samping yang serius dari pengobatan Obat Anti Tuberkulosis (OAT), khususnya yang melibatkan isoniazid, rifampisin, dan pirazinamid. Penelitian ini bertujuan untuk menilai sejauh mana N-Acetylcysteine (NAC) dapat mengurangi risiko hepatotoksisitas pada pasien TBC yang menerima terapi OAT di RSUD Pasar Rebo. Penelitian ini non eksperimental analitik dengan pendekatan kohort retrospektif. Metode ini digunakan untuk melihat hubungan N-Acetylcysteine dalam menurunkan risiko hepatotoksisitas pada pasien TBC yang menjalani terapi di RSUD Pasar Rebo. Hasil penelitian menunjukkan adanya perbedaan yang signifikan pada kadar SGOT (p=0,001) dan SGPT (p=0,004) antara kelompok yang diberikan N-Acetylcystein dan yang tidak. Selain itu, ditemukan pula hubungan yang signifikan antara jenis kelamin dan efektivitas N-Acetylcystein (SGOT p=0,038; SGPT p=0,019), tetapi tidak ada hubungan yang signifikan dengan usia. Kesimpulan dari penelitian ini adalah penggunaan N-Acetylcysteine terbukti efektif dalam mengurangi risiko hepatotoksisitas yang disebabkan oleh terapi OAT.

Keywords


N-Acetylcystein; Hepatotoksisitas; Obat anti tuberkulosis; SGOT; SGPT

Full Text:

PDF

References


Baniasadi, S., Eftekhari, P., Tabarsi, P., Fahimi, F., Raoufy, M. R., Masjedi, M. R., & Velayati, A. A. (2010). Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. European Journal of Gastroenterology and Hepatology, 22(10), 1235–1238. https://doi.org/10.1097/MEG.0b013e32833aa11b

Banjuradja, I., & Singh, G. (2020). Mekanisme hepatotoksisitas dalam tatalaksana tuberkulosis pada gangguan hati. Indonesia Journal Chest |, 7(2), 55–64.

Cohen, Z. Z., & Blest-Hopley, G. (2025). Females in Psychedelic Research: A Perspective for Advancing Research and Practice. ACS Pharmacology and Translational Science. https://doi.org/10.1021/acsptsci.5c00255

Dirjen P2P. (2023). Laporan Program Penanggulangan Tuberkulosis Tahun 2022. In Kemenkes RI. https://tbindonesia.or.id/pustaka_tbc/laporan-tahunan-program-tbc-2021/

Jiang, F., Yan, H., Liang, L., Du, J., Jin, S., Yang, S., Wang, H., Hu, T., Zhu, Y., Wang, G., Hu, Y., Cai, T., & Aithal, G. P. (2021). Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver International, 41(7), 1565–1575. https://doi.org/10.1111/liv.14896

Kristini, T., & Hamidah, R. (2020). Potensi Penularan Tuberculosis Paru pada Anggota Keluarga Penderita. Jurnal Kesehatan Masyarakat Indonesia, 15(1), 24. https://doi.org/10.26714/jkmi.15.1.2020.24-28

Mahakalkar, S., Nagrale, D., Gaur, S., Urade, C., Murhar, B., & Turankar, A. (2017). N-acetylcysteine as an add-on to Directly Observed Therapy Short-I therapy in fresh pulmonary tuberculosis patients: A randomized, placebo-controlled, double-blinded study. Perspectives in Clinical Research, 8(3), 132–136. https://doi.org/10.4103/2229-3485.210450

Mangoni, A. A., & Jackson, S. H. D. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology, 57(1), 6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x

Moosa, M. S., Maartens, G., Gunter, H., Allie, S., Chughlay, M. F., Setshedi, M., Wasserman, S., Stead, D. F., Hickman, N., Stewart, A., Sonderup, M., Spearman, C. W., & Cohen, K. (2021). A Randomized Controlled Trial of Intravenous N-Acetylcysteine in the Management of Anti-tuberculosis Drug-Induced Liver Injury. Clinical Infectious Diseases, 73(9), E3377–E3383. https://doi.org/10.1093/cid/ciaa1255

Naqvi, I. H., Mahmood, K., Talib, A., & Mahmood, A. (2015). Antituberculosis Drug-Induced Liver Injury: An Ignored Fact, Assessment of Frequency, Patterns, Severity and Risk Factors. Open Journal of Gastroenterology, 05(12), 173–184. https://doi.org/10.4236/ojgas.2015.512027

Papi, A., Di Stefano, A. F. D., & Radicioni, M. (2021). Pharmacokinetics and Safety of Single and Multiple Doses of Oral N-Acetylcysteine in Healthy Chinese and Caucasian Volunteers: An Open-Label, Phase I Clinical Study. Advances in Therapy, 38(1), 468–478. https://doi.org/10.1007/s12325-020-01542-4

Ramappa, V., & Aithal, G. P. (2013). Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. Journal of Clinical and Experimental Hepatology, 3(1), 37–49. https://doi.org/10.1016/j.jceh.2012.12.001

Rebo, R. P. (n.d.). Sejarah Berdirinya RSUD Pasar Rebo Visi dan Misi Rumah Sakit Motto RSUD Pasar Rebo Kebijakan Mutu.

Sari, D. P., & Andriani, V. (2024). KAJIAN HUBUNGAN PENGGUNAAN OBAT ANTITUBERKULOSIS FASE AWAL TERHADAP KADAR SGOT-SGPT PADA PASIEN TBC. 5, 10783–10792.

Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., Bernardo, J., Venkataramanan, R., & Sterling, T. R. (2006). An official ATS statement: Hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine, 174(8), 935–952. https://doi.org/10.1164/rccm.200510-1666ST

Schwalfenberg, G. K. (2021). N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks). Journal of Nutrition and Metabolism, 2021. https://doi.org/10.1155/2021/9949453

Soldin, O. P., & Mattison, D. R. (2009). Sex differences in pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 48(3), 143–157. https://doi.org/10.2165/00003088-200948030-00001

Sukumaran, D., Usharani, P., Paramjyothi, G. K., Subbalaxmi, M. V. S., Sireesha, K., & Ali, M. A. (2023). No TitleA study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Indian Journal of Tuberculosis. https://doi.org/https://doi.org/10.1016/j.ijtb.2022.05.012

Turnheim, K. (2003). When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Experimental Gerontology, 38(8), 845–845. https://doi.org/https://doi.org/10.1016/S0531-5565(03)00133-5

Yani, M. S., & Singh, G. (2015). Efek Hepatoprotektif N-Asetilsistein dalam Mencegah Drug-Induced Liver Injury Akibat Obat Antituberkulosis : Laporan Kasus Berbasis Bukti. Indonesian Journal of CHEST, 2(2), 86–90.

Zhong, T., Fan, Y., Dong, X. L., Guo, X., Wong, K. H., Wong, W. T., He, D., & Liu, S. (2021). An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis. Frontiers in Pharmacology, 12(November), 1–9. https://doi.org/10.3389/fphar.2021.708522




DOI: https://doi.org/10.31764/lf.v7i1.35299

Refbacks

  • There are currently no refbacks.


EDITORIAL OFFICE: